| CELC Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the CELC shares outstanding history going back to 9/20/2017:
Also see: CELC Market Cap History CELC YTD Return |
CELC Shares Outstanding History — Celcuity Share Count Over Time
As of 5/7/2026 Celcuity has 48.77 million CELC shares outstanding. Investors often track the CELC shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows CELC share count trends over time, with 36 historical shares outstanding datapoints presented, dating back to 9/20/2017.
| CELC Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELC Historical Shares Outstanding: +21.05% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CELC Stock Price Chart |
| About Celcuity Inc |
| Celcuity Inc. is a clinical-stage biotechnology company developing targeted therapies for solid tumors. Its lead candidate, gedatolisib, is a small molecule inhibitor targeting all Class I PI3K isoforms and mTOR sub-complexes (mTORC1 and mTORC2). Initial clinical programs focus on treating hormone receptor positive (HR+), HER2-negative (HER2-), advanced or metastatic breast cancer, and metastatic castration-resistant prostate cancer. The VIKTORIA-1 trial evaluates gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- advanced breast cancer. The CELsignia diagnostic platform analyzes live tumor cells to identify new cancer patient groups. We show 36 historical shares outstanding datapoints in our coverage of CELC's shares outstanding history. Understanding the changing numbers of CELC shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like CELC versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching CELC by allowing them to research CELC shares outstanding history as well as any other stock in our coverage universe. |
| CELC Current Stock Quote |
Quotes delayed 20 minutes  Free CELC Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| CELC Share Performance |
| Shares Outstanding Peers |
| Celcuity (CELC) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
CELG Shares Outstanding History CELL Shares Outstanding History CELU Shares Outstanding History CELZ Shares Outstanding History CEMI Shares Outstanding History CERC Shares Outstanding History CERE Shares Outstanding History CERS Shares Outstanding History CFMS Shares Outstanding History CFRX Shares Outstanding History More Healthcare companies » |
CELC Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
